CVAC (CureVac NV) FCF Margin % : -4,692.33% (As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CureVac NV's Free Cash Flow for the three months ended in Mar. 2025 was $-45.3 Mil. CureVac NV's Revenue for the three months ended in Mar. 2025 was $1.0 Mil. Therefore, CureVac NV's FCF Margin % for the quarter that ended in Mar. 2025 was -4,692.33%.

As of today, CureVac NV's current FCF Yield % is 13.73%.

The historical rank and industry rank for CureVac NV's FCF Margin % or its related term are showing as below:

CVAC' s FCF Margin % Range Over the Past 10 Years
Min: -836.03 Med: -569.52 Max: 972.05
Current: 28.92

During the past 7 years, the highest FCF Margin % of CureVac NV was 972.05%. The lowest was -836.03%. And the median was -569.52%.

CVAC's FCF Margin % is ranked better than
92.99% of 999 companies
in the Biotechnology industry
Industry Median: -102.06 vs CVAC: 28.92

CureVac NV FCF Margin % Historical Data

The historical data trend for CureVac NV's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV FCF Margin % Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

972.05

-836.03

-562.74

-601.00

15.58

CureVac NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
FCF Margin %	Get a 7-Day Free Trial															-821.47	-669.17	71.02	-477.78	-4,692.33

Competitive Comparison of CureVac NV's FCF Margin %

For the Biotechnology subindustry, CureVac NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CureVac NV's FCF Margin % falls into.

Save Embed

;

Save Embed

;

CureVac NV FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CureVac NV's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	87.337	/	560.398
	=	15.58 %

CureVac NV's FCF Margin for the quarter that ended in Mar. 2025 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2025 )	/	Revenue (Q: Mar. 2025 )
	=	-45.281	/	0.965
	=	-4,692.33 %

CureVac NV FCF Margin % Related Terms

Thank you for viewing the detailed overview of CureVac NV's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

1CVAC:Italy 0A9E:UK 5CV:Germany CVAC:Austria

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.